Long-lasting effects of recreational drugs of abuse on the central nervous system

Neuroscientist

Volumn 3, Issue 6, 1997, Pages 399-411

  Mccann, Una D ^a   Lowe, Kelly A ^b   Ricaurte, George A ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Amphetamines; CNS; Drug abuse; Long term effects; Neurotoxicity; Serotonin

Indexed keywords

EID: 0000301321     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385849700300613     Document Type: Review

References (195)

1. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996;15;379: 606-612.
2. Volkow ND, Ding YS, Fowler JS, Wang GJ. Cocaine addiction: hypothesis derived from imaging studies with PET. J Addict Dis 1996;15:55-71.
3. Eisner B. Ecstasy: the MDMA story. Berkeley (CA): Ronin Publishing; 1989.
4. Shulgin AT, Nichols DE. Characterization of three new psychotomimetics. In: Stillman R, Willette R, editors. The psychopharmacology of hallucinogens. New York: Pergamon Press; 1978. p. 74-83.
5. Greer G, Strassman RJ. Information on ecstasy. Am J Psychiatry 1985;1482:391.
6. Greer G, Tolbert P. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986;18:319-327.
7. Downing J. The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 1986;18: 335-340.
8. Peroutka SJ. Incidence of recreational use of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on an undergraduate campus. N Engl J Med 1987;317:1542-1543.
9. Lawn JC. Schedules of controlled substances: scheduling of 3,4-methylenedioxymethamphetamine (MDMA) into Schedule I of the Controlled Substance Act. Fed Reg 1986;51:36552-36560.
10. Anon. Drug culture. Lancet 1992;339:117.
11. Abbot A, Concar D. A trip into the unknown. New Scientist 1992;29:30-34.
12. Solowij N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of ecstasy users and their experiences with the drug. Brit J Addiction 1992;87:1161-1172.
13. Randall T. Ecstasy-fueled "rave" parties become dances of death for English youths. JAMA 1992;268:1505-1506.
14. Cregg MT, Tracey JA. Ecstasy abuse in Ireland. Ir Med J 1993;86:118-120.
15. Cuomo M, Dyment P, Gammino V. Increasing use of ecstasy (MDMA) and other hallucinogens on a college campus. J Am Coll Health 1994;42:271-274.
16. Schmidt CJ, Wu L, Lovenberg W. Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analog. Eur J Pharmacol 1986;124:175-178.
17. Stone DM, Stahl DS, Hanson GL, Gibb JW. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine on monoaminergic systems in the rat brain. Eur J Pharmacol 1986;128:41-48.
18. Commins DL, Vosmer G, Virus R, Woolverton W, Schuster C, Seiden L. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987;241:338-345.
19. Schmidt CJ. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 1987; 240:1-7.
20. Slikker W, Ali SF, Scallet C, Frith CH, Newport GD, Bailey JR. Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 1988;94: 448-457.
21. Ricaurte GA, DeLanney LE, Irwin I, Langston JW. Toxic effects of MDMA on central serotonergic neurons in the primate: Importance of route and frequency of drug administration. Brain Res 1988;446:165-168.
22. Slikker W Jr, Holson RR, Ali SF, et al. Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology 1989;10:529-542.
23. Insel TR, Battaglia G, Johannessen JN, Marra S, De Souza EB. 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther 1989;249:713-720.
24. Schmidt CJ, Taylor VL. Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 1987;36: 4095-1102.
25. Stone DM, Hanson GL, Gibb JW. Differences in the central serotonergic effects of 3,4-methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology 1987;26:1657-1661.
26. 3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 1987;242:911-916.
27. O'Hearn EG, Battaglia G, DeSouza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 1988;8:2788-2803.
28. Wilson MA, Ricaurte GA, Molliver ME. Distinct morphological classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience 1989;28:121-137.
29. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn EG, Wilson MA. Neurotoxicity of MDMA and related compounds: Anatomic studies. Ann N Y Acad Sci 1990;600:640-664.
30. Axt KJ, Mamounas LA, Molliver ME. Structural features of amphetamine neurotoxicity in the brain. In: Cho A, Segal DS, editors. Amphetamines and their analogs: neuropsychopharmacology, toxicology, and abuse. New York: Academic Press; 1994. p. 315-367.
31. Kosofsky B, Molliver M. The serotoninergic innervation of the cerebral cortex: different classes of axon terminals arise from dorsal and median raphe nuclei. Synapse 1987;1:153-168.
32. Battaglia G, Yeh SY, DeSouza EB. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 1988;29:269-274
33. Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA. Serotonergic recovery after (+)3,4-(methylenedioxy)methamphetamine injury: Observations in rodents. J Pharmacol Exp Ther 1993;264:1484-1491.
34. Ricaurte GA, Katz JL, Martello MB. Lasting effects of (±)3,4-methylenedioxymethamphetamine on central serotonergic neurons in non-human primates. J Pharmacol Exp Ther 1992;261:616-622.
35. Fischer CA, Hatzidimitriou G, Katz JL, Ricaurte GA. Reorganization of ascending serotonin axon projections in animals previously exposed to the recreational drug 3,4-methylenedioxymethamphetamine. J Neurosci 1995;15:5476-5485.
36. Sachs C, Jonsson G. 5.7-dihydroxytryptamine induced changes in the postnatal development of central 5-hydroxytryptamine neurons. Med Biol 1975;53:156-164.
37. Wiklund L, Björklund A, Nobin A. Regeneration of serotonin neurons in the rat brain after 5.6-dyhydroxytryptamine-induced axotomy. Ann N Y Acad Sci 1978;305:370-384.
38. Schneider GE. Early lesions of the superior colliculus: factors affecting the formation of abnormal retinal projections. Brain Behav Evol 1973;8:73-109.
39. Jonsson G, Pycock C, Fuxe K, Sachs C. Changes in the development of central noradrenaline neurons after neonatal administration of 6-hydroxydopamine. J Neurochem 1974;22:419-426.
40. 3H]noradrenaline uptake, catecholamines, and catecholamine synthetic and catabolic enzymes in rat brain following neonatal 6-hydroxydopamine treatment. Med Biol 1976;54:286-297.
41. Levitt P, Moore R. Organization of brainstem noradrenaline hyperinnervation following neonatal 6-hydroxydopamine treatment in rat. Anat Embryol (Berl) 1980;158:133-150
42. Jonsson G, Sachs C. Changes in the development of central noradrenergic neurons after neonatal axon lesions. Brain Res Bull 1982;9:641-650.
43. Gustafson EL, Moore RY. Noradrenoline neuron plasticity in developing rat brain: effects of neonatal 6-hydroxydopamine demonstrated by dopamine-hydroxylase immunocytochemistry. Dev Brain Res 1987;37:143-155.
44. Jonsson G, Pollare T, Hallman H, Sachs C. Developmental plasticity of central serotonin neurons after 5,7-dyhydroxytryptamine treatment. Ann N Y Acad Sci 1978;305:328-345.
45. Björklund A, Wiklund L. Mechanisms of regrowth of the bulbospinal serotonin system following 5,6-dihydroxytryptamine induced axotomy. Brain Res 1980;191:109-127.
46. Frankfurt M, Azmitia E. Regeneration of serotonergic fibers in the hypothalamus following unilateral 5,7-dihydroxytryptamine injection. Brain Res 1984;298:273-282.
47. Pare M, Descarries L, Wiklund L. Innervation and reinnervation of rat inferior olive by neurons containing serotonin and substance P: an immunohistochemical study after 5,6-dihydroxytryptamine lesioning. J Neurocytol 1987;16:155-167.
48. Frankfurt M, Beaudet A. Ultrastructural organization of regenerated serotonin axons in the dorsomedial hypothalamus of the adult rat. J Neurocytol 1987;16:799-809.
49. Fritschy J, Grzanna R. Restoration of ascending noradrenergic projections by residual locus ceruleus neurons: compensatory response to neurotoxin-induced cell death in the adult rat brain. J CompNeurol 1992;321:421-441.
50. Pare M, Descarries L, Quirion R. Up-regulation of 5-HT2 and NK-1 receptors associated with serotonin/substance P hyperinnervation in the rat inferior olive. Neuroscience 1992;51:97-106.
51. Ricaurte GA, Forno LS, Wilson MA, et al. (±)3,4-Methylenedioxymethamphetamine (MDMA) selectively damages central serotonergic neurons in non-human primates. JAMA 1988;260: 51-55.
52. Mordenti J, Chappell W. The use of interspecies scaling in toxicokinetics. In: Yacobi A, Kelly K, Batra V, editors. Toxicokinetics in new drug development. New York: Pergamon Press; 1989. p. 42-96.
53. Chappell W, Mordenti J. Extrapolation of toxicological and pharmacological data from animals to humans. In: Testa B, editor. Advances in drug research. Vol. 20. San Diego: Academic Press; 1991. p. 1-116.
54. Ricaurte GA, Delanney LE, Wiener SG, Irwin I, Langsten JW. 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res 1988;474:359-363.
55. Ricaurte GA, Finnegan KT, Irwin I, Langston JW. Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann N Y Acad Sci 1990; 600:699-710.
56. Peroutka SJ, Pascoe N, Faull KF. Monoamine metabolites in the CSF of recreational users of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy"). Res Commun Subst Abuse 1987;8: 125-138.
57. Ballenger J, Post R, Goodwin F. Neurochemistry of cerebrospinal fluid in normal individuals. In: Wood JH, editor. Neurobiology of cerebrospinal fluid. New York: Plenum Press; 1980. p. 143-156.
58. McCann UD, Ridenour A, Shaham Y, Ricaurte GA. Brain serotonergic neurotoxicity after MDMA ('ecstasy'): a controlled study in humans. Neuropsychopharmacology 1994;10:129-138.
59. McCann UD, Ricaurte GA. Strategies for detecting partial monoamine depletions in humans. NIDA Res Monogr 1993;136:53-62.
60. McCann U, Slate S, Ricaurte G. Adverse reactions with 3,4-methylenedioxy-methamphetamine (MDMA; "ecstasy"). Drug Saf 1996;15:107-115.
61. Harries DP, De Silva R. Ecstasy and intracerebral haemorrhage. Scott Med J 1992;37:476.
62. Gledhill JA, Moore DF, Bell D, Henry JA. Subarachnoid hemorrhage associated with MDMA abuse. J Neurol Neurosurg Psych 1993;56:1036-1037.
63. Hughes JC, McCabe M, Evans RJ. Intracranial haemorrhage associated with ingestion of "ecstasy." Archives of Emergency Medicine 1993;10:372-374.
64. Manchanda S, Connolly MJ. Cerebral infarction in association with ecstasy abuse. Postgrad Med J 1993;69:874-875.
65. Hanyu S, Ikeguchi K, Imai H, et al. Cerebral infarction associated with 3,4-methylenedioxymethamphetamine ("ecstasy") abuse. Eur Neurol 1995;35:173.
66. McCann UD, Ricaurte GA. Lasting neuropsychiatric sequelae of (±) methylenedioxymethamphetamine ("ecstasy") in recreational users. J Clin Psychopharmacol 1991;11:302-305.
67. McGuire P, Fahy T. Chronic paranoid psychosis after misuse of MDMA ('ecstasy'). Brit Med J 1991;302:607.
68. Schifano F. Chronic atypical psychosis associated with MDMA ('ecstasy') abuse. Lancet 1991;338:1335.
69. Creighton FJ, Black DL, Hyde CE. Ecstasy psychosis and flashbacks. Br J Psychiatry 1991;159:713-715.
70. McGuire PK, Cope H, Fahy T. Diversity of psychopathology associated with use of 3,4-Methylenedioxymethaphetamine (ecstasy). Br J Psychiatry 1994;165:391-395.
71. Pallanti S, Mazzi D. MDMA (ecstasy) precipitation of panic disorder. Biol Psychiatry 1992;32:91-95.
72. Series H, Boeles S, Dorkins E, Peveler R. Psychiatric complications of "Ecstasy" use. J Psychopharmacol 1994;8:60-61.
73. Benazzi F, Mazzoli M. Psychiatric illness associated with "ecstasy." Lancet 1991;338:1520.
74. Meltzer HY, Lowy M. The serotonin hypothesis of depression. In: Meltzer H, editor. Psychopharmacology: the third generation of progress. New York: Raven Press; 1987. p. 513-526.
75. Dowling GP, McDonough ET, Bost RO. Eve and ecstasy: a report of five deaths associated with the use of MDEA and MDMA. JAMA 1987;257:1615-1617.
76. Ricaurte GA, Finnegan K, Nichols D, DeLanney L, Irwin I, Langston J. 3,4-Methylenedioxyethylamphetamine ("MDE"), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain. Eur J Pharmacol 1987;137:265-268.
77. Ricaurte G, Bryan G, Strauss L, Seiden L, Schuster C. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985;229:986-988.
78. Seiden LS, Ricaurte GA. Neurotoxicity of methamphetamine and related drugs. In: Meltzer HY, editor. Psychopharmacology - a generation of progress. New York: Raven Press; 1987. p. 359-366.
79. Woolverton WL, Ricaurte GA, Forno LS, Seiden LS. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res 1989;486:73-78.
80. Litchenfeld PJ, Rubin DB, Feldman RS. Subarachnoid hemorrhage precipitated by cocaine snorting. Arch Neurol 1984;41: 223-224.
81. Levine SR, Washington JM, Jefferson MF, et al. "Crack" cocaine-associated stroke. Neurology 1987;37:1849-1853.
82. Kaku DA, Lowenstein DH. Emergence of recreational drug abuse as a major risk factor for stroke in young adults. Ann Intern Med 1990;113:821-827.
83. Levin SR, Brust JC, Futrell N, et al. Cerebrovascular complications of the use of the "crack" form of alkaloidal cocaine. N Engl J Med 1990;323:699-704.
84. Levine SR, Brey RL. Antiphospholipid antibodies and ischemic cerebrovascular disease [review]. Semin Neurol 1991;11:329-338.
85. Daras M, Tuchman AJ, Koppel BS, Samkoff LM, Weitzner I, Marc J. Neurovascular complications of cocaine. Acta Neurol Scand 1994;90:124-129.
86. Qureshi A, Akbar M, Czander E, Safdar K, Janssen R, Frankel M. Crack cocaine use and stroke in young patients. Neurology 1997;48:341-345.
87. Levine SR, Welch KM. Cocaine and stroke. Stroke 1988;19:779-783.
88. Klonoff DC, Andrews BT, Obana WG. Stroke associated with cocaine use. Arch Neurol 1989;46:989-993.
89. Peterson PL, Rozler M, Jacobs I, Wilner HI. Neurovascular complications of cocaine abuse. J Neuropsychiatry Clin Neurosci 1991;3:143-149.
90. Brust JCM. Stroke and substance abuse. In: Barnett HJ, Stein BM, Yatsu FM, editors. Stroke: pathophysiology, diagnosis, and management. 2nd ed. New York: Churchill Livingstone; 1992. p. 875-93.
91. Green RM, Kelly KM, Gabrielson T, Levine SR, Vanderzant C. Multiple intracerebral hemorrhages after smoking "crack" cocaine. Stroke 1990;21:957-962.
92. Kibayashi K, Mastri AR, Hirsch CS. Cocaine induced intracerebral hemorrhage: analysis of predisposing factors and mechanisms causing hemorrhagic strokes. Hum Pathol 1995;26:659-663.
93. Volkow ND, Mullani N, Gould LK, Adler S, Krajewski D. Cerebral blood flow in chronic cocaine users: a study in positron emission tomography. Br J Psychiatry 1988;152:641-648.
94. Strickland TL, Mena I, Villaneuve-Meyer J, et al. Cerebral perfusion and neuropsychological consequences of chronic cocaine use. J Neuropsychiatry Clin Neurosci 1993;5:419-427.
95. Weber DA, Franceschi D, Ivanovic M, et al. SPECT and planar brain imaging in crack abuse: iodine-123iodoamphetamine uptake and localization. J Nucl Med 1993;34:899-907.
96. Holman BL, Mendelson J, Garada B, et al. Regional cerebral blood flow improves with treatment in chronic correlations in the CNS. J Neurosci 1993;9:3884-3898.
97. Pascual-Leone A, Dhuna A, Anderson DC. Cerebral atrophy in habitual cocaine abusers: a planimetric CT study. Neurology 1991;41:34-38.
98. Volkow ND, Fowler JS, Wolf AP, et al. Changes in brain glucose metabolism in cocaine dependence and withdraw. Am J Psychiatry 1991;148:621-626.
99. Volkow ND, Fowler JS, Wang G-J, et al. Decreased dopamine D2 receptors availability is associated with reduced frontal me tabolism in cocaine abusers. Synapse 1993;14:169-177.
100. 3H]WIN 35428 binding sites in human striatum. Brain Res 1993; 628:17-25.
101. Staley JK, Hearn WL, Ruttenber AJ, et al. High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. J Pharmacol Exp Ther 1994;271: 1678-1685.
102. Wilson JM, Levey AL, Bergeron C, et al. Striatal dopamine, dopamine transporter and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 1996;40:428-439.
103. Hurd YL, Herkenham M. Molecular alterations in the neostriatum of human cocaine addicts. Synapse 1993;13:357-369.
104. Hitri A, Casanova MF, Kleinman JE, Wyatt RJ. Fewer dopamine transporter receptors in the prefrontal cortex of cocaine users. Am J Psychiatry 1994;151:1074-1076.
105. Staley JK, Mash DC. Adaptive increase in D3 dopamine receptors in the brain reward circuits in cocaine fatalities. J Neurosci 1996;16:6100-6106.
106. Kalivas P, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev 1991;16:223-244.
107. Wyatt RJ, Karoun F, Suddath R, Fawcett RW. Persistently decreased brain dopamine levels and cocaine. JAMA 1988;259:2996.
108. Kleven MS, Woolverton WL, Seiden LS. Lack of long-term monoamine depletions following repeated or continuous exposure to cocaine. Brain Res Bull 1988;21:233-237.
109. Peris J, Boyson SJ, Cass WA, et al. Persistence of neurochemical changes in dopamine systems after repeated cocaine administration. J Pharmacol Exp Ther 1990;253:38-44.
110. Karoum F, Suddath RL, Wyatt RJ. Chronic cocaine and rat brain catecholamines: long-term reduction in hypothalamic and frontal cortex dopamine metabolism. Eur J Pharmacol 1990;186:1-8.
111. 3H]dopamine uptake in vitro in rat nucleus accumbens but not striatum. Brain Res 1990;531:338-341.
112. 3H]mazindol-labelling of dopamine transporter in rat nucleus accumbens. Eur J Pharmacol 1991;203:141-144.
113. Yeh SY, DeSouza EB. Lack of neurochemical evidence for neurotoxic effects of repeated cocaine administration in rats on monoamine neurons. Drug Alcohol Depend 1991;27:51-61.
114. Farfel GM, Kleven MS, Woolverton WL, et al. Effects of repeated injections of cocaine on catecholamine receptor binding sites, dopamine transporter binding sites and behavior in rhesus monkeys. Brain Res 1992;578:235-243.
115. Wilson JM, Kish SJ. The vesicular dopamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 1996;16:3507-3510.
116. Hope BT, Nye HE, Kelz MB, et al. Induction of a long-lasting AP-1 complex composed of altered fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 1994;13: 1235-1244.
117. Schuster CR. The United States' drug abuse scene: an overview. Clin Chem 1987;33:7B-12B.
118. Scallet AC, Uemura E, Andrews AM, et al. Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC). Brain Res 1987;436:193-198.
119. Landfield PW, Cadwallader LB, Vinsant S. Quantitative changes in hippocampal structure following long-term exposure to delta-9-tetrahydrocannabinol: possible mediation by the glucocorticoid system. Brain Res 1988;443:47-62.
120. Harper JW, Heath RG, Myers WA. Effects of cannabis sativa on ultrastructure of the synapse in monkey brain. J Neurosci Res 1977;3:87-93.
121. Heath RG, Fitzjarrel AT, Fontana CJ, Garey RE. Cannabis sativa: effects on brain function and ultrastructure in rhesus monkeys. Biol Psychiatry 1980;15:657-691.
122. Scallet AC. Neurotoxicology of cannabis and THC: A review of chronic exposure studies in animals. Pharmacol Biochem Behav 1991;40:671-676.
123. Smith DE. Acute and chronic toxicity of marijuana. J Psychedelic Drugs 1968;2:37-47.
124. Wikler A. Aspects of tolerance to and dependence on cannabis. Ann N Y Acad Sci 1976;282:126-147.
125. Tennant FS, Groesbeck CJ. Psychiatric effects of hashish. Arch Gen Psychiatry 1972;33:383-386.
126. Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986; 38:1-20.
127. Abood ME, Martin BR. Neurobiology of marijuana abuse. Trends Pharmacol Sci 1992;13:201-206.
128. Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry 1993;163:141-149.
129. Victor M, Adams RD. The effect of alcohol on the nervous system. Res Publ Assoc Nerv Ment Dis 1953;32:526.
130. Charness ME, Simon RP, Greenberg DA. Ethanol and the nervous system. N Engl J Med 1989;321:442.
131. Schenker S. Effects of alcohol on the brain: clinical features, pathogenesis, and treatment. In: Lieber CS, editor. Medical disorders of alcoholism: pathogenesis and treatment. Philadelphia: Saunders; 1982. p. 480.
132. Messing RO, Greenberg DA. Alcohol and the nervous system. In: Aminoff MJ, editor. Neurology and general medicine. New York: Churchill Livingstone; 1995. p. 615-629.
133. Torvik A, Lindboe CF, Rogde S. Brain lesions in alcoholics: a neuropathologic study with clinical complications. J Neurol Sci 1982;56:233.
134. Samson HH, Harris RA. Neurobiology of alcohol abuse. Trends Pharmacol Sci 1992;13:206.
135. Goebel HH, Herman-BenZur P. Central pontine myelinolysis. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology. Vol. 28. Amsterdam: Elsevier; 1976. p. 285.
136. Messert B, Orison WW, Hawkins MJ, Quaglieri CE. Central pontine myelinolysis: consideration on etiology, diagnosis, and treatment. Neurology 1979;29:147.
137. Victor M, Adams RD, Cole M. The acquired Wilsonian type of chronic hepatocerebral degeneration. Medicine (Baltimore) 1965; 44:345.
138. Victor M, Adams RD, Collins GHP. The Wernicke-Korsakoff syndrome and related neurologic disorders due to alcoholism and malnutrition. Philadelphia: Davis; 1989.
139. Reuler JB, Girard DE, Cooney TG. Wernicke's encephalopathy. N Engl J Med 1985;312:1035.
140. Rubin E. Alcoholic myopathy in heart and skeletal muscle. N Engl J Med 1979;301:28.
141. Walker DW, Barnes DE, Zornetzer SF, et al. Neuronal loss in hippocampus induced by prolonged ethanol consumption in rats. Science 1980;209:711-713.
142. Walker DW, Heaton MB, Lee N, King MA, Hunter BE. Effect of chronic ethanol on the septohippocampus system: a role for neurotrophic fectors? Alcohol Clin Exp Res 1993;17:12-18.
143. Domino E. Neurobiology of phencyclidine (Sernyl), a drug with an unusual spectrum of pharmacological activity. Int Rev Neurobiol 1964;6:303-347.
144. Johnstone M, Evans V, Baigel S. Sernyl (CI-395) in clinical anesthesia Br J Anaesth 1958;31:433-439.
145. Olney JW, Farber NB. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 1995;13:335.
146. Jaffe JH. Drug addiction and drug abuse. In: Goodman A, Gilman S, editors. Pharmacological basis of therapeutics. Elmsford (NY): Pergamon Press; 1990. p. 522-573.
147. Domino E, Luby E. Abnormal mental states induced by phencyclidine as a model of schizophrenia. In: Domino E, editor. PCP (Phencyclidine): historical and current perspectives. Ann Arbor: NPP Books; 1981. p. 401-418.
148. Siegel R. Phencyclidine and ketamine intoxication: a study of four populations of recreational users. In: Petersen R, Stilman R, editors. Phencyclidine (PCP) abuse: an appraisal. NIDA Res Monogr 1978;21:119-147.
149. Aniline O, Pitts F. Phencyclidine (PCP): a review and perspectives. CRC Crit Rev Toxicol 1982;10:145-177.
150. Lerner SE, Burns RS. Phencyclidine use among youth: history, epidemiology and acute and chronic intoxication. In: Peterson RC, Stillman RC, editors. PCP phencyclidine abuse: an appraisal. NIDA research monograph 21. Rockville (MD): National Institute on Drug Abuse; 1978. p. 66-118.
151. Weibel SL, Wolf HH. Opiate modification of intracranial self-stimulation in the rat. Pharmacol Biochem Behav 1979;10:71-78.
152. Cosgrove J, Newell T. Recovery of neuropsychological functions during reduction in use of phencyclidine. J Clin Psychol 1991; 47:159-169.
153. Olney J, Labruyere J, Price M. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989;244:1360-1362.
154. Gao X, Shirakawa F, Tamminga C. Delayed regional metabolic actions of phencyclidine. Eur J Pharmacol 1993;241:7-25.
155. Nakki R, Koistinaho J, Sharp F, Sagar SM. Cerebellar toxicity of phencyclidine. J Neurosci 1995;15:2097-2108.
156. Ellison G, Switzer R III. Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuroreport 1993;5:17-20.
157. Ellison G. Neuronal degeneration following both competitive and non-competitive NMDA antagonists. Neuroreport 1994;5:2688-2692.
158. Olney JW, Labruyere J, Wang G, Wozniak DF. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1995; 254:1515-1518.
159. Farber N, Price M, Labruyere J, et al. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol Psychiatry 1993;34:119-121.
160. Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Brain Res Rev 1995;20:250-267.
161. Abraham HD, Aldridge AM. Adverse consequences of lysergic acid diethylamine. Addiction 1993;88:1327-1334.
162. Diaz JL, Huttunen MO. Persistent increase in brain serotonin turnover after chronic administration of LSD in the rat. Science 1971;174:62-64.
163. Rosencrans JA, Lovell RA, Friedman DX. Effects of lysergic acid diethylamide on the metabolism of brain 5-hydroxytryptamine. Biochem Pharmacol 1967;16:2011-2021.
164. Lee EH, Geyer MA. Persistent effects of chronic administration of LSD on intracellular serotonin content in rat midbrain. Neuropharmacology 1980;19:1005-1007.
165. King W, Ellison G. Long-lasting alterations in behavior and brain neurochemistry following continuous low-level LSD administration. Pharmacol Biochem Behav 1989;33:69-73.
166. Garratt JC, Alreja M, Aghajanian GK. LSD has high efficacy relative to serotonin in enhancing the cationic current Ih: intracellular studies in rat facial motoneurons. Synapse 1993;13:123-134.
167. Wolters EC, van Wijngaarder GK, Stam FC, et al. Leucoencephalopathy after inhaling poisoned heroin pyrosylate. Lancet 1982;2:1233-1237.
168. Hungerbuhler H, Waespe W. Leukoenzephalopathie nach inhalation von heroin-pyrolysat. Schweiz Med Wochenschr 1990; 120:1801-1805.
169. Schiffer D, Brignolio F, Giordana T, Mongini T, Migheli A, Palmucci L. Spongiform encephalopathy in addicts inhaling preheated heroin. Clin Neuropathol 1985;4:174-180.
170. Sempere AP, Posada I, Ramo C, Cabello A. Spongiform leucoencephalopathy after inhaling heroin. Lancet 1991;338:320.
171. Tan TP, Algra PR, Valk J, Wolters EC. Toxic leukoencephalopathy after inhalation of poisoned heroin. Am J Neurorad 1992; 15:175-178.
172. Gulowsen C, Anderson S. Leucoencephalopathy after inhalation of heroin. A case report. J Neurol Neurosurg Psychiatry 1996; 60:694-695.
173. Kriegstein A, Armitage B, Kim P. Heroin inhalation and progressive spongiform leukoencephalopathy. N Engl J Med 1997; 336:589-590.
174. Strang J, Gurling H. Computerized tomography and neuropsychological assessment in long-term high-dose heroin addicts. Br J Addict 1989;84:1011-1019.
175. Oehmichen M, Meiner C, Reiter A, Birkholz M. Neuropathology in non-human immunodeficiency virus-infected drug addicts: hypoxic brain damage after chronic intravenous drug abuse. Acta Neuropathol (Berl) 1996;91:642-646.
176. Brust J, Richter R. Stroke associated with addiction to heroin. J Neurol 1976;39:194-199.
177. Caplan LR, Hier DB, Banks G. Current concepts of cerbrovascular disease-stroke: stroke and drugs of abuse. Stroke 1982; 13:869.
178. Chenery H, Murdoch B. A case of mixed transcortical aphasia following drug overdose. Br J Disord Commun 1986;21:381-392.
179. Jensen R, Olsen T, Winther B. Severe non-occlusive ischemic stroke in young heroin addicts. Acta Neurol Scand 1990;81:354-357.
180. Zuckerman GB, Ruiz DC, Keller IA, Brooks J. Neurologic complications following intranasal administration of heroin in an adolescent. Ann Pharmacother 1996;30:778-781.
181. Greenwood RJ. Lumbar plexitis and rhabdomyolysis following abuse of heroin. Postgrad Med J 1974;50:772-773.
182. Litt IF, Schonberg SK. Medical complications of drug abuse in adolescents. Med Clin North Am 1975;59:1445-1452.
183. Richter R, Rosenberg R. Transverse myelitis associated with heroin addiction. JAMA 1968;206:1255-1257.
184. Schein P, Yessayan L, Mayman C. Acute transverse myelitis associated with intravenous opium. Neurology 1971;21:101-102.
185. Judice DJ, LeBlanch HJ, McGarry PA. Spinal cord vasculitis presenting as a spinal cord tumor in a heroin addict. Case report. J Neurosurg 1978;48:131-134.
186. Ell JJ, Uttley D, Silver JR. Acute myelopathy in association with heroin addiction. J Neurol Neurosurg Psychiatry 1981;44:448-450.
187. Goodhart LC, Loizou LA, Anderson M. Heroin myelopathy. J Neurol Neurosurg Psychiatry 1982;45:562-563.
188. Protass LM. Delayed postanoxic encephalopathy after heroin use. Ann Intern Med 1971;74:738-739.
189. King J, Richards M, Tress B. Cerebral arteritis associated with heroin abuse. Med J Aust 1978;2:444-445.
190. Citron B, Halpern M, McCarron M, et al. Necrotizing angiitis associated with drug abuse. N Engl J Med 1970;283:1003-1011.
191. Haaxma R, van Boxtel A, Brouwer WH, et al. Motor function in a patient with bilateral lesions of the globus pallidus. Movement disorders 1995;10:761-767.
192. Benassi G, Rinaldi R, Azzimondi G, Stracciari A, D'Alessandro R, Pazzaglia P. Acute generalized dystonia due to a bilateral lesion of basal ganglia mainly affecting the nuclei pallidi. Ital J Neurol Sci 1996;17:71-73.
193. Rose JS, Branchey M, Buydens-Branchey L, et al. Cerebral perfusion in early and late opiate withdrawal: a technetium-99m-HMPAO SPECT study. Psychiatry Res 1996;67:39-47.
194. London ED, Margolin RA, Wong DF, et al. Cerebral glucose utilization in human heroin addicts: case reports from a positron emission tomography study. Res Comm Subst Abuse 1989;10: 141-144.
195. Langston JW, Ballard PA, Tetrad JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine analog synthesis. Science 1983;219:979-980.